Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of Patients Undergoing CAR-T Cell Therapy in Germany.
Penack O, Dreger P, Ajib S, Ayuk F, Baermann BN, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel PG, Schroers R, von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D. Penack O, et al. Among authors: jentzsch m. Oncol Res Treat. 2024;47(3):65-75. doi: 10.1159/000536201. Epub 2024 Jan 10. Oncol Res Treat. 2024. PMID: 38198763 Free PMC article.
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Gerhardt K, Jentzsch M, Georgi T, Sretenović A, Cross M, Bach E, Monecke A, Leiblein S, Hoffmann S, Todorović M, Bila J, Sabri O, Schwind S, Franke GN, Platzbecker U, Vučinić V. Gerhardt K, et al. Among authors: jentzsch m. Front Oncol. 2021 Sep 16;11:737645. doi: 10.3389/fonc.2021.737645. eCollection 2021. Front Oncol. 2021. PMID: 34604075 Free PMC article.
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW, Kurch L, Franke GN, Jentzsch M, Schwind S, Perez-Fernandez C, Petermann N, Merz M, Metzeler K, Borte G, Hoffmann S, Herling M, Denecke T, Kluge R, Sabri O, Platzbecker U, Vučinić V. Georgi TW, et al. Among authors: jentzsch m. J Cancer Res Clin Oncol. 2023 Aug;149(9):6131-6138. doi: 10.1007/s00432-023-04587-4. Epub 2023 Jan 20. J Cancer Res Clin Oncol. 2023. PMID: 36662305 Free PMC article.
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J. Lübke J, et al. Among authors: jentzsch m. Leukemia. 2024 Apr;38(4):810-821. doi: 10.1038/s41375-024-02186-x. Epub 2024 Mar 6. Leukemia. 2024. PMID: 38448757 Free PMC article.
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, de Witte TM, Itzykson RA, Jentzsch M, Platzbecker U, Santini V, Sanz GF, Scheid C, Solary E, Valent P, Greco R, Sánchez-Ortega I, Yakoub-Agha I, Pleyer L. Onida F, et al. Among authors: jentzsch m. Blood. 2024 Mar 17:blood.2023023476. doi: 10.1182/blood.2023023476. Online ahead of print. Blood. 2024. PMID: 38493484 Free article.
97 results